Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes.

Jenny L Wiley1, Billy R Martin

  • 1Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, PO Box 980613, Richmond, VA 23298-0613, USA. jwiley@hsc.vcu.edu

Chemistry and Physics of Lipids
|December 31, 2002
PubMed
Summary

Researchers suggest novel cannabinoid receptors may exist beyond CB1 and CB2. Anandamide and WIN 55212-2 show activity in CB1 knockout mice, indicating potential new targets for cannabis research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.

Progress in neuro-psychopharmacology & biological psychiatry·2024
Same author

Δ<sup>9</sup>-tetrahydrocannabinol discrimination: Effects of route of administration in mice.

Drug and alcohol dependence reports·2023
Same author

Δ<sup>9</sup>-Tetrahydrocannabinol Effects on Respiration and Heart Rate Across Route of Administration in Female and Male Mice.

Cardiovascular toxicology·2023
Same author

Experimenter administered Δ<sup>9</sup>-THC decreases nicotine self-administration in a rat model.

Pharmacology, biochemistry, and behavior·2023
Same author

The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism.

Pharmacology, biochemistry, and behavior·2023
Same author

In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.

Pharmacology, biochemistry, and behavior·2022

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Delta-9-Tetrahydrocannabinol (delta(9)-THC) is the main psychoactive compound in marijuana, primarily interacting with CB1 and CB2 cannabinoid receptors.
  • Existing research suggests other cannabinoids, such as anandamide and WIN 55212-2, might activate previously undiscovered cannabinoid receptors.

Purpose of the Study:

  • To investigate the potential existence of novel cannabinoid receptors beyond the known CB1 and CB2.
  • To explore the pharmacological actions of anandamide and WIN 55212-2 in the absence of CB1 receptors.

Main Methods:

  • Utilized CB1 knockout mice to differentiate receptor-mediated effects.
  • Assessed in vivo pharmacological effects of cannabinoids.
  • Measured [35S]GTPgammaS binding in vitro in both wildtype and CB1 knockout mouse tissues.

Related Experiment Videos

Main Results:

  • Anandamide exhibited in vivo effects in CB1 knockout mice not seen with delta(9)-THC, which could not be attributed to rapid metabolism.
  • Anandamide and WIN 55212-2 stimulated [35S]GTPgammaS binding in both wildtype and CB1 knockout mice.
  • Delta(9)-THC only stimulated [35S]GTPgammaS binding in wildtype mice.

Conclusions:

  • The findings suggest the potential existence of additional cannabinoid receptors in both the brain and peripheral tissues.
  • Anandamide's actions in CB1 knockout mice do not appear to be mediated by vanilloid VR1 receptors, further supporting novel receptor hypotheses.